Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Acta Dermato-Venereologica|November 24, 2022
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay RegistryCeleste M Boesjes, Esmé Kamphuis, Nicolaas P A Zuithoff, et al.JAMA Dermatology|October 16, 2024
Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic DermatitisLisa P van der Rijst, Esmé Kamphuis, Marie L A Schuttelaar, et al.Expert Opinion on Biological Therapy|July 13, 2026
Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registryFlorence Vroman, Octavian I Bacoş-Cosma, Lisa C de Krosse, et al.The British Journal of Dermatology|November 8, 2023
Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial)Aviël Ragamin, Renske Schappin, Marlies de Graaf, et al.Trials|December 13, 2021
The effectiveness of antibacterial therapeutic clothing based on silver or chitosan as compared with non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis (ABC trial): study protocol for a pragmatic randomized controlled trialAviël Ragamin, Karin B Fieten, Ron A Tupker, et al.JAMA Dermatology|August 10, 2022
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Nicolaas P A Zuithoff, et al.The British Journal of Dermatology|May 13, 2023
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registryLotte S Spekhorst, Celeste M Boesjes, Laura Loman, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2026
Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDayLian F van der Gang, Nicolaas P A Zuithoff, Inge M Haeck, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 3, 2025
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay resultsLian F van der Gang, Keneshka Atash, Nicolaas P A Zuithoff, et al.Journal of the American Academy of Dermatology|April 23, 2024
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registryJunfen Zhang, Celeste M Boesjes, Laura Loman, et al.Pageof 6